Aura Announces Upsizing of Non-Brokered Private Placement
08 Janvier 2019 - 2:13PM
Aura Health Inc. (the "
Company" or
“
Aura”) (
CSE:BUZZ) is pleased to
announce that due to increased demand it has upsized its previously
announced non-brokered private placement (see press release dated
January 7, 2019) from $1,500,000 to up to $1,650,000 (the
“
Offering”). The Offering is expected to close on
or about January 10, 2019 (the “
Closing Date”).
The net proceeds from the Offering shall be used for general
working capital and to advance the Company’s involvement in two
Israeli cannabis companies, HolyCanna and CannabiSendak.
Aura intends to issue up to 11,000,000 units of
the Company (each a “Unit” and collectively, the
“Units”) at a price of $0.15 per Unit, for gross
proceeds of $1,650,000. Each Unit is comprised of one common share
in the capital of the Company (each a “Common
Share”) and one-half of one common share purchase warrant,
exercisable at $0.25 for a period of 24 months from the date of
issuance.
In connection with the Offering, Aura expects to
compensate finders who introduced subscribers to the Company (the
“Placees”) by way of (i) an aggregate cash
commission of 8% of the proceeds placed by the Placees and (ii)
issuing that number of non-transferrable finders warrants equal to
8% of the number of Units subscribed to by the Placees (each a
“Finder’s Warrant”). Each Finder’s Warrant will be
exercisable to purchase one Common Share at an exercise price of
$0.25 for a period of 24 months from the date of issuance.
All securities issued pursuant to the Offering
will be subject to a hold period of four months plus one day from
the Closing Date. The Offering remains subject to approval of the
Canadian Securities Exchange. Aura expects that insiders of the
Company will participate in the Offering.
About Aura Health Inc.
Aura is building an international network of
vertically integrated cannabis assets. The Company holds
convertible debt that converts to 54% equity of HolyCanna, a
cultivation and nursery license holder in Israel, and has an LOI in
place to acquire the majority of CannabiSendak, the builder of a
network of high-profile dispensaries in Israel. Aura also owns a
30% interest in four medical marijuana clinics in the U.S. Sun
Belt, with an option to increase its interest in three of the
clinics to 51%.
For further information, please
contact:
Daniel Cohen, CEO Aura Health
Inc. (647) 202-1824
David Posner, ChairmanAura
Health Inc. (647) 985-6727
Caution Regarding Forward-Looking
Information:
THE CANADIAN SECURITIES EXCHANGE HAS NOT
REVIEWED NOR DOES IT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR
ACCURACY OF THIS RELEASE.
This news release may contain forward-looking
statements and information based on current expectations. These
statements should not be read as guarantees of future performance
or results. Such statements involve known and unknown risks,
uncertainties and other factors that may cause actual results,
performance or achievements to be materially different from those
implied by such statements. Such statements include submission of
the relevant documentation within the required timeframe and to the
satisfaction of the relevant regulators, completing the acquisition
of the applicable real estate and raising sufficient financing to
complete the Company's business strategy. There is no certainty
that any of these events will occur. Although such statements are
based on management's reasonable assumptions, there can be no
assurance that such assumptions will prove to be correct. We assume
no responsibility to update or revise them to reflect new events or
circumstances.
The Company's securities have not been
registered under the U.S. Securities Act of 1933, as amended (the
"U.S. Securities Act"), or applicable state securities laws, and
may not be offered or sold to, or for the account or benefit of,
persons in the United States or "U.S. Persons", as such term is
defined in Regulation S under the U.S. Securities Act, absent
registration or an applicable exemption from such registration
requirements. This press release shall not constitute an offer to
sell or the solicitation of an offer to buy nor shall there be any
sale of the securities in the United States or any jurisdiction in
which such offer, solicitation or sale would be unlawful.
Additionally, there are known and unknown risk
factors which could cause the Company's actual results, performance
or achievements to be materially different from any future results,
performance or achievements expressed or implied by the
forward-looking information contained herein. All forward-looking
information herein is qualified in its entirety by this cautionary
statement, and the Company disclaims any obligation to revise or
update any such forward-looking information or to publicly announce
the result of any revisions to any of the forward-looking
information contained herein to reflect future results, events or
developments, except as required by law.
Pharmadrug (CSE:BUZZ)
Graphique Historique de l'Action
De Déc 2024 à Jan 2025
Pharmadrug (CSE:BUZZ)
Graphique Historique de l'Action
De Jan 2024 à Jan 2025